Elicio Therapeutics, Inc.ELTXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank11
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P11
Within normal range
vs 5Y Ago
-0.9x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-26.01%
202448.40%
202333.05%
2022-64.93%
202125.02%
202030.52%
2019225.51%
20180.00%
20130.00%
20120.00%